47 results
8-K
EX-10.1
oxg gr859kq
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
D
si6mg
19 Feb 21
$10.24M in equity / options, sold $10.24M, 18 investors
9:26am
8-K
EX-99.1
5pj7ywww6p9ckmozzh0
5 Nov 20
Processa Pharmaceuticals Announces the Appointment of
9:00am
8-K
EX-1.1
cogd9c1b7 i6z
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
y90cg2ntzbnpqblk
5 Oct 20
Prospectus supplement with pricing info
4:16pm
8-K
EX-10.1
eja6sds3wxoso
27 Aug 20
Entry into a Material Definitive Agreement
9:30am